The refractory macular edema (RME) seriously affects the patient's vision due to its repetition and ineffective drug response. RME is mainly related to the inflammatory pathway and angiogenesis pathway. At present, microglia activation and angiogenesis have also been widely focused on. With the promotion of the concept of precision diagnosis and treatment, intraocular fluid is becoming a popular evidence-based method. The detection and evaluation of aqueous humor factors can provide more accurate evidences and guidance for the treatment of RME. The purpose of this article is to review the treatment prediction and assessment progress of aqueous humor cytokines for the RME, giving evidence to provide a basis for expanding the diagnosis and treatment ideas of RME and guiding the development of personalized medical treatment.
Get full access to this article
View all access options for this article.
References
1.
AlraoujiNN, AboussekhraA. Tocilizumab inhibits IL-8 and the proangiogenic potential of triple negative breast cancer cells. Mol Carcinog, 2021; 60(1):51–59; doi: 10.1002/mc.23270.
2.
AnY, ParkSP, KimYK. Aqueous humor inflammatory cytokine levels and choroidal thickness in patients with macular edema associated with branch retinal vein occlusion. Int Ophthalmol, 2021; 41(7):2433–2444; doi: 10.1007/s10792-021-01798-x.
3.
AugustineJ, PavlouS, AliI, et al.IL-33 deficiency causes persistent inflammation and severe neurodegeneration in retinal detachment. J Neuroinflammation, 2019; 16(1):251; doi: 10.1186/s12974-019-1625-y.
4.
AzarDT.Corneal angiogenic privilege: Angiogenic and antiangiogenic factors in corneal avascularity, vasculogenesis, and wound healing (an American Ophthalmological Society thesis). Trans Am Ophthalmol Soc, 2006; 104:264–302.
5.
BodaghiB, GendronG, WechslerB, et al.Efficacy of interferon alpha in the treatment of refractory and sight threatening uveitis: A retrospective monocentric study of 45 patients. Br J Ophthalmol, 2007; 91(3):335–339; doi: 10.1136/bjo.2006.101550.
6.
BogradA, FuchsD, BächtigerJ, et al.Long-term efficacy of TNF-alpha inhibitors on persistent uveitic macular edema: A Swiss multicenter cohort study. Ocul Immunol Inflamm, 2022;1–8; doi: 10.1080/09273948.2022.2075761.
7.
BresslerNM, BeaulieuWT, GlassmanAR, et al.Persistent macular thickening following intravitreous aflibercept, bevacizumab, or ranibizumab for central-involved diabetic macular edema with vision impairment: A secondary analysis of a randomized clinical trial [published correction appears in JAMA Ophthalmol. 2018; 136(5):601]. JAMA Ophthalmol, 2018; 136(3):257–269; doi: 10.1001/jamaophthalmol.2017.6565.
8.
BrunnerPM, Suárez-FariñasM, HeH, et al.The atopic dermatitis blood signature is characterized by increases in inflammatory and cardiovascular risk proteins [published correction appears in Sci Rep 2018;8(1):8439]. Sci Rep, 2017; 7(1):8707; doi: 10.1038/s41598-017-09207-z.
9.
ButlerNJ, SuhlerEB, RosenbaumJT. Interferon alpha 2b in the treatment of uveitic cystoid macular edema. Ocul Immunol Inflamm, 2012; 20(2):86–90; doi: 10.1080/09273948.2019.1589526.
10.
ChenM, ZhaoJ, AliIHA, et al.Cytokine signaling protein 3 deficiency in myeloid cells promotes retinal degeneration and angiogenesis through arginase-1 up-regulation in experimental autoimmune uveoretinitis. Am J Pathol, 2018a;188(4):1007–1020; doi: 10.1016/j.ajpath.2017.12.021.
11.
ChenY, YangP, LiF, et al.The effects of Th17 cytokines on the inflammatory mediator production and barrier function of ARPE-19 cells. PLoS One, 2011; 6(3):e18139; doi: 10.1371/journal.pone.0018139.
12.
ChenY, ZhongM, YuanG, et al.Interleukin-17 induces angiogenesis in vitro via CXCL8 and CCL2 in retinal pigment epithelium. Mol Med Rep, 2018b;17(3):4627–4632; doi: 10.3892/mmr.2018.8460.
13.
ChengSC, Huang WCS P, angJH, et al.Quercetin inhibits the production of IL-1β-induced inflammatory cytokines and chemokines in ARPE-19 cells via the MAPK and NF-κB signaling pathways. Int J Mol Sci, 2019; 20(12):2957; doi: 10.3390/ijms20122957.
14.
ChoiMY, JeeD, KwonJW. Characteristics of diabetic macular edema patients refractory to anti-VEGF treatments and a dexamethasone implant. PLoS One, 2019; 14(9):e0222364; doi: 10.1371/journal.pone.0222364.
DesiderioS. Pumping the breaks on B cell development. J Exp Med, 2016; 213(2):140; doi: 10.1084/jem.2132insight1.
17.
Figueras-RocaM, MatasJ, LlorensV, et al.Systemic contribution of inflammatory mediators to the severity of diabetic and uveitic macular edema. Graefes Arch Clin Exp Ophthalmol, 2021; 259(9):2695–2705; doi: 10.1007/s00417-021-05149-5.
18.
Figueras-RocaM, MolinsB, Sala-PuigdollersA, et al.Peripheral blood metabolic and inflammatory factors as biomarkers to ocular findings in diabetic macular edema. PLoS One, 2017; 12(3):e0173865; doi: 10.1371/journal.pone.0173865.
19.
GilliesMC, SuT. Interferon-alpha 2b enhances barrier function of bovine retinal microvascular endothelium in vitro. Microvasc Res, 1995; 49(3):277–288; doi: 10.1006/mvre.1995.1024.
20.
GlassmanAR, WellsJA, 3rd, JosicK, et al.Five-year outcomes after initial aflibercept, bevacizumab, or ranibizumab treatment for diabetic macular edema (Protocol T Extension Study). Ophthalmology, 2020; 127(9):1201–1210; doi: 10.1016/j.ophtha.2020.03.021.
21.
GnanasekaranS, Bandala-SanchezE, KolicM, et al. The association between intravitreal ranibizumab therapy and serum cytokine concentrations in patients with diabetic macular edema. Mol Vis 2020; 26:246–256.
22.
GruberCN, PatelRS, TrachtmanR, et al. Mapping systemic inflammation and antibody responses in multisystem inflammatory syndrome in children (MIS-C). Cell 2020;183(4):982.e14–995.e14; doi: 10.1016/j.cell.2020.09.034.
23.
HendrickAM, GibsonMV, KulshreshthaA. Diabetic retinopathy. Prim Care, 2015; 42(3):451–464; doi: 10.1016/j.pop.2015.05.005.
24.
HillierRJ, OjaimiE, WongDT, et al.Aqueous humor cytokine levels as biomarkers of disease severity in diabetic macular edema. Retina, 2017; 37(4):761–769; doi: 10.1097/IAE.0000000000001210.
25.
HuangF, WangK, ShenJ. Lipoprotein-associated phospholipase A2: The story continues. Med Res Rev, 2020; 40(1):79–134; doi: 10.1002/med.21597.
26.
HuangQ, DingJ, GongM, et al.Effect of miR-30e regulating NK cell activities on immune tolerance of maternal-fetal interface by targeting PRF1. Biomed Pharmacother, 2019; 109:1478–1487; doi: 10.1016/j.biopha.2018.09.172.
27.
IshikawaK, KannanR, HintonDR. Molecular mechanisms of subretinal fibrosis in age-related macular degeneration. Exp Eye Res, 2016; 142:19–25; doi: 10.1016/j.exer.2015.03.009.
28.
JorgovanovicD, SongM, WangL, et al.Roles of IFN-γ in tumor progression and regression: A review. Biomark Res, 2020; 8:49; doi: 10.1186/s40364-020-00228-x.
29.
KarkiR, SharmaBR, TuladharS, et al. Synergism of TNF-α and IFN-γ triggers inflammatory cell death, tissue damage, and mortality in SARS-CoV-2 infection and cytokine shock syndromes. Cell 2021;184(1):149.e17–168.e17; doi: 10.1016/j.cell.2020.11.025.
30.
KorhonenE, PiippoN, HyttiM, et al.SQSTM1/p62 regulates the production of IL-8 and MCP-1 in IL-1β-stimulated human retinal pigment epithelial cells. Cytokine, 2019; 116:70–77; doi: 10.1016/j.cyto.2018.12.015.
31.
KosmaczewskaA, Przeździecka-DołykJ, Turno-KręcickaA, et al.Imbalance in PB IL-17-secreting and regulatory cells in pars planitis is associated with dysregulation of IFN-γ-secreting cells, especially in patients with clinical complications. Mediators Inflamm, 2020; 2020:9175083; doi: 10.1155/2020/9175083.
32.
KwonJW, KimB, JeeD, et al.Aqueous humor analyses of diabetic macular edema patients with subretinal fluid [published correction appears in Sci Rep 2022;12(1):1205]. Sci Rep, 2021; 11(1):20985; doi: 10.1038/s41598-021-00442-z.
33.
LeeWJ, KangMH, SeongM, et al.Comparison of aqueous concentrations of angiogenic and inflammatory cytokines in diabetic macular oedema and macular oedema due to branch retinal vein occlusion. Br J Ophthalmol, 2012; 96(11):1426–1430; doi: 10.1136/bjophthalmol-2012-301913.
34.
LejoyeuxR, DiwoE, ValletH, et al.INFLIXIMAB and ADALIMUMAB in uveitic macular edema. Ocul Immunol Inflamm, 2018; 26(7):991–996; doi: 10.1080/09273948.2018.1498110.
35.
Levy-ClarkeG, JabsDA, ReadRW, et al. Expert panel recommendations for the use of anti-tumor necrosis factor biologic agents in patients with ocular inflammatory disorders. Ophthalmology 2014;121(3):785.e3–796.e3; doi: 10.1016/j.ophtha.2013.09.048.
36.
LiangY, YanB, MengZ, et al.Comparison of inflammatory and angiogenic factors in the aqueous humor of vitrectomized and non-vitrectomized eyes in diabetic macular edema patients. Front Med (Lausanne), 2021; 8:699254; doi: 10.3389/fmed.2021.699254.
37.
LimSW, Bandala-SanchezE, KolicM, et al.The influence of intravitreal ranibizumab on inflammation-associated cytokine concentrations in eyes with diabetic macular edema. Invest Ophthalmol Vis Sci, 2018; 59(13):5382–5390; doi: 10.1167/iovs.17-23325.
38.
MackensenF, JakobE, SpringerC, et al. Interferon versus methotrexate in intermediate uveitis with macular edema: Results of a randomized controlled clinical trial. Am J Ophthalmol 2013;156(3):478.e1–486.e1; doi: 10.1016/j.ajo.2013.05.002.
39.
MalekiA, StephensonAP, HajizadehF. Topical interferon alpha 2b in the treatment of refractory diabetic macular edema. J Ophthalmic Vis Res, 2020; 15(4):453–458; doi: 10.18502/jovr.v15i4.7785.
40.
MassaH, PipisSY, AdewoyinT, et al.Macular edema associated with non-infectious uveitis: Pathophysiology, etiology, prevalence, impact and management challenges. Clin Ophthalmol, 2019; 13:1761–1777; doi: 10.2147/OPTH.S180580.
41.
MastropasquaR, D'AloisioR, Di NicolaM, et al.Relationship between aqueous humor cytokine level changes and retinal vascular changes after intravitreal aflibercept for diabetic macular edema. Sci Rep, 2018; 8(1):16548; doi: 10.1038/s41598-018-35036-9.
42.
MatasJ, LlorençV, FonollosaA, et al.Systemic regulatory T cells and IL-6 as prognostic factors for anatomical improvement of uveitic macular edema. Front Immunol, 2020; 11:579005; doi: 10.3389/fimmu.2020.579005.
43.
MelderRJ, KoenigGC, WitwerBP, et al.During angiogenesis, vascular endothelial growth factor and basic fibroblast growth factor regulate natural killer cell adhesion to tumor endothelium. Nat Med, 1996; 2(9):992–997; doi: 10.1038/nm0996-992.
44.
MesquidaM, DrawnelF, LaitPJ, et al.Modelling macular edema: The effect of IL-6 and IL-6R blockade on human blood-retinal barrier integrity in vitro. Transl Vis Sci Technol, 2019; 8(5):32; doi: 10.1167/tvst.8.5.32.
45.
MidenaE, MiceraA, FrizzieroL, et al.Sub-threshold micropulse laser treatment reduces inflammatory biomarkers in aqueous humour of diabetic patients with macular edema. Sci Rep, 2019; 9(1):10034; doi: 10.1038/s41598-019-46515-y.
46.
NomaH, FunatsuH, MimuraT, et al.Visual prognosis and vitreous molecules after vitrectomy for macular edema with branch retinal vein occlusion. Clin Ophthalmol, 2011; 5:223–229; doi: 10.2147/OPTH.S16552.
47.
NomaH, MimuraT, YasudaK, et al.Role of soluble vascular endothelial growth factor receptors-1 and -2, their ligands, and other factors in branch retinal vein occlusion with macular edema. Invest Ophthalmol Vis Sci, 2014; 55(6):3878–3885; doi: 10.1167/iovs.14-13961.
48.
NomaH, MimuraT, YasudaK, et al.Cytokines and recurrence of macular edema after intravitreal ranibizumab in patients with branch retinal vein occlusion. Ophthalmologica, 2016a;236(4):228–234; doi: 10.1159/000451062.
49.
NomaH, MimuraT, YasudaK, et al.Possible molecular basis of bevacizumab therapy for macular edema in branch retinal vein occlusion. Retina, 2016b;36(9):1718–1725; doi: 10.1097/IAE.0000000000000983.
50.
NomaH, YasudaK, MimuraT, et al.Relationship between retinal blood flow and cytokines in central retinal vein occlusion. BMC Ophthalmol, 2020a;20(1):215; doi: 10.1186/s12886-020-01486-x.
51.
NomaH, YasudaK, MimuraT, et al.Retinal microcirculation and cytokines as predictors for recurrence of macular edema after intravitreal ranibizumab injection in branch retinal vein occlusion. J Clin Med, 2020b;10(1):58; doi: 10.3390/jcm10010058.
52.
NomaH, YasudaK, MimuraT, et al.Relationship between choroidal findings and growth factors, cytokines, and other inflammatory mediators after intravitreal ranibizumab injection in patients with macular edema secondary to branch retinal vein occlusion. Retina, 2022; 42(4):744–751; doi: 10.1097/IAE.0000000000003362.
53.
OhH, TakagiH, TakagiC, et al.The potential angiogenic role of macrophages in the formation of choroidal neovascular membranes. Invest Ophthalmol Vis Sci, 1999; 40(9):1891–1898.
54.
PodkowinskiD, Orlowski-WimmerE, ZlabingerG, et al.Aqueous humour cytokine changes during a loading phase of intravitreal ranibizumab or dexamethasone implant in diabetic macular oedema. Acta Ophthalmol, 2020; 98(4):e407–e415; doi: 10.1111/aos.14297.
55.
PrattCH, VadigepalliR, ChakravarthulaP, et al. Transcriptional regulatory network analysis during epithelial-mesenchymal transformation of retinal pigment epithelium. Mol Vis 2008; 14:1414–1428.
56.
RytelewskaE, KiezunM, ZaobidnaE, et al.Chemerin as a modulator of angiogenesis and apoptosis processes in the corpus luteum of pigs: An in vitro study. Biol Reprod, 2021; 105(4):1002–1015; doi: 10.1093/biolre/ioab126.
57.
SabanerMC, AkdoganM, DoğanM, et al.Inflammatory cytokines, oxidative and antioxidative stress levels in patients with diabetic macular edema and hyperreflective spots. Eur J Ophthalmol, 2021; 31(5):2535–2545; doi: 10.1177/1120672120962054.
58.
SauterMM, BrandtCR. Primate neural retina upregulates IL-6 and IL-10 in response to a herpes simplex vector suggesting the presence of a pro-/anti-inflammatory axis. Exp Eye Res, 2016; 148:12–23; doi: 10.1016/j.exer.2016.05.003.
59.
SelvarajSK, GiriRK, PerelmanN, et al.Mechanism of monocyte activation and expression of proinflammatory cytochemokines by placenta growth factor. Blood, 2003; 102(4):1515–1524; doi: 10.1182/blood-2002-11-3423.
60.
ShimuraM, YasudaK, MotohashiR, et al.Aqueous cytokine and growth factor levels indicate response to ranibizumab for diabetic macular oedema. Br J Ophthalmol, 2017; 101(11):1518–1523; doi: 10.1136/bjophthalmol-2016-309953.
61.
ShirayaT, KatoS, ArakiF, et al.Aqueous cytokine levels are associated with reduced macular thickness after intravitreal ranibizumab for diabetic macular edema. PLoS One, 2017; 12(3):e0174340; doi: 10.1371/journal.pone.0174340.
62.
SingerM, TanCS, BellD, et al.Area of peripheral retinal nonperfusion and treatment response in branch and central retinal vein occlusion. Retina, 2014; 34(9):1736–1742.; doi: 10.1097/IAE.0000000000000148.
63.
SongS, YuX, ZhangP, et al.Increased levels of cytokines in the aqueous humor correlate with the severity of diabetic retinopathy. J Diabetes Complications, 2020; 34(9):107641; doi: 10.1016/j.jdiacomp.2020.107641.
64.
StiefelHC, KopplinLJ, AlbiniT, et al.Treatment of refractory cystoid macular edema with pegylated interferon alfa-2A: A retrospective chart review. Ocul Immunol Inflamm, 2021; 29(3):566–571; doi: 10.1080/09273948.2019.1687729.
65.
SuN, ZhaoN, WangG, et al.Association of MCP-1 rs1024611 polymorphism with diabetic foot ulcers. Medicine (Baltimore), 2018; 97(28):e11232; doi: 10.1097/MD.0000000000011232.
66.
SuryawanshiA, Veiga-PargaT, ReddyPB, et al.IL-17A differentially regulates corneal vascular endothelial growth factor (VEGF)-A and soluble VEGF receptor 1 expression and promotes corneal angiogenesis after herpes simplex virus infection. J Immunol, 2012; 188(7):3434–3446; doi:10.4049/jimmunol.1102602.
67.
Torres-CostaS, Alves ValenteMC, Falcão-ReisF, et al.Cytokines and growth factors as predictors of response to medical treatment in diabetic macular edema. J Pharmacol Exp Ther, 2020; 373(3):445–452; doi: 10.1124/jpet.119.262956.
68.
WangX, WongK, OuyangW, et al.Targeting IL-10 family cytokines for the treatment of human diseases. Cold Spring Harb Perspect Biol, 2019; 11(2):a028548; doi: 10.1101/cshperspect.a028548.
69.
WautierJL, WautierMP. Cellular and molecular aspects of blood cell-endothelium interactions in vascular disorders. Int J Mol Sci, 2020; 21(15):5315; doi: 10.3390/ijms21155315.
70.
WuJ, ZhongY, YueS, et al.Aqueous humor mediator and cytokine aberrations in diabetic retinopathy and diabetic macular edema: A systematic review and meta-analysis. Dis Markers, 2019; 2019:6928524; doi: 10.1155/2019/6928524.
71.
XiaJP, WangS, ZhangJS. The anti-inflammatory and anti-oxidative effects of conbercept in treatment of macular edema secondary to retinal vein occlusion. Biochem Biophys Res Commun, 2019; 508(4):1264–1270; doi: 10.1016/j.bbrc.2018.12.049.
72.
XuH, CaiM, ZhangX. Effect of the blockade of the IL-23-Th17-IL-17A pathway on streptozotocin-induced diabetic retinopathy in rats. Graefes Arch Clin Exp Ophthalmol, 2015; 253(9):1485–1492; doi: 10.1007/s00417-014-2842-9.
73.
YangKB, SunXY, SunLP, et al.Aqueous humor cytokine levels and rebound macular edema after conbercept treatment in patients with central retinal vein occlusion. Retina, 2021; 41(4):834–843; doi: 10.1097/IAE.0000000000002918.
74.
YangT, LinQ, ZhaoM, et al.IL-37 is a novel proangiogenic factor of developmental and pathological angiogenesis. Arterioscler Thromb Vasc Biol, 2015; 35(12):2638–2646; doi: 10.1161/ATVBAHA.115.306543.
75.
YenihayatF, ÖzkanB, KasapM, et al.Vitreous IL-8 and VEGF levels in diabetic macular edema with or without subretinal fluid. Int Ophthalmol, 2019; 39(4):821–828; doi: 10.1007/s10792-018-0874-6.
76.
ZhaoM, HuY, YuY, et al.Involvement of IL-37 in the pathogenesis of proliferative diabetic retinopathy. Invest Ophthalmol Vis Sci, 2016; 57(7):2955–2962; doi: 10.1167/iovs.15-18505.
77.
ZhengY, RaoYQ, LiJK, et al.Age-related pro-inflammatory and pro-angiogenic changes in human aqueous humor. Int J Ophthalmol, 2018; 11(2):196–200; doi: 10.18240/ijo.2018.02.03.
78.
ZhouRH, YaoM, LeeTS, et al.Vascular endothelial growth factor activation of sterol regulatory element binding protein: A potential role in angiogenesis. Circ Res, 2004; 95(5):471–478; doi: 10.1161/01.RES.0000139956.42923.4A.
79.
ZouR, WangMH, ChenY, et al.Hydrogen-rich saline attenuates acute lung injury induced by limb ischemia/reperfusion via down-regulating chemerin and NLRP3 in rats. Shock, 2019; 52(1):134–141; doi: 10.1097/SHK.0000000000001194.
